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Hypertension is a risk factor for several cardiovascular diseases and oxidative stress suggested to be involved in the pathophysiology.
Antihypertensive drug Clonidine action in ameliorating oxidative stress was not well studied. Therefore, this study investigate the
effect of Clonidine on oxidative stressmarkers and nitric oxide (NO) in SHR and nitric oxide synthase inhibitor, N-nitro-L-arginine
methyl ester (L-NAME) administered SHR. Male rats were divided into four groups [SHR, SHR+Clonidine (SHR-C), SHR+L-
NAME, SHR+Clonidine+L-NAME(SHRC+L-NAME)]. Rats (SHRC) were administered with Clonidine (0.5mg kg−1 day−1) from
4 weeks to 28 weeks in drinking water and L-NAME (25mg kg−1 day−1) from 16 weeks to 28 weeks to SHRC+L-NAME. Systolic
blood pressure (SBP) was measured. At the end of 28 weeks, all rats were sacrificed and in their heart homogenate, oxidative stress
parameters and NO was assessed. Clonidine treatment significantly enhanced the total antioxidant status (TAS) (𝑃 < 0.001) and
reduced the thibarbituric acid reactive substances (TBARS) (𝑃 < 0.001) and protein carbonyl content (PCO) (𝑃 < 0.05). These
data suggest that oxidative stress is involved in the hypertensive organ damage and Clonidine not only lowers the SBP but also
ameliorated the oxidative stress in the heart of SHR and SHR+L-NAME.
1. Introduction
Globally, near one billion people have hypertension; of these,
two-thirds are in developing countries, killing nearly 8 mil-
lion people worldwide every year and nearly 1.5 million peo-
ple each year in South-East Asia region approximately one-
third of the adult population in this region has high blood
pressure [1]. The Sixth Reports of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure (JNCVI) define hypertension or high
blood pressure to be present if it is persistently at or above
140/90mmHg.
Hypertension is a risk factor for several cardiovascular
diseases such as atherosclerosis or myocardial infarction [2],
kidney failure [3], stroke, and death [4].
Growing evidence indicated that oxidative stress plays
an important role in the pathophysiology of hypertension
[5]. Hypertension is associated with imbalance of oxidant
antioxidant status which causes alteration in lipid peroxida-
tion [6] superoxide dismutase and glutathione peroxidase [7]
and higher production in hydrogen peroxide [8].
Nitric oxide (NO) (endothelium-derived relaxing factor)
is synthesised in biological system by nitric oxide synthase
(NOS) and has a strong vasodilatory effect [9]. NOS inhibitor
such as N-nitro-L-arginine methyl ester (L-NAME) has a
causal role in oxidative stress [10–12] as well as promotes
persistent hypertension and progressive cardiovascular dam-
age [13]. Zhou and Frohlich [13] developed and established
the L-NAME/SHRmodel thatmimics the pathophysiological
alterations associated with naturally-occurring progressive
impairment of cardiac and renal functions and structure.
They have reviewed series of studies designed using the
L-NAME/SHR to investigate the effect of antihypertensive
agents on prevention, development, progression, and even
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reversal of hypertensive nephrosclerosis. Each report docu-
mented the pathophysiological actions by the intervention
of an antihypertensive agent either concomitantly with or
subsequently following L-NAME. However, the studies were
focusing on pathophysiological effect of calcium antagonists,
angiotensine converting enzyme inhibitors and aldosterone
antagonist. Therefore, using the L-NAME/SHR model, we
would like to determine the effects of Clonidine, an a-
adrenoceptor agonists, another class of antihypertensive drug
on oxidative stress markers [thiobarbituric acid reactive sub-
stances (TBARS), protein carbonyl (PCO), total antioxidant
status (TAS)] and nitric oxide level in the heart of SHR and
SHR+L-NAME.
2. Methods
This study was approved by the Animal Ethics and Welfare
Committee of Universiti Sains Malaysia. Male SHR aged 4
weeks were obtained from the Animal Research and Service
Centre (ARASC), Health Campus Universiti Sains Malaysia,
and housed in individual cages in standard environment
(25–27∘C) room temperature under 12 hours light and 12
hours dark cycle (lights on 0700–1900 hours). The animals
were fed with commercial rat food pellet and Clonidine
(Sigma, USA) was given through drinking water. Rats
were divided into 4 groups: (1) SHR (untreated), (2) SHR
treated with Clonidine (0.5mg kg−1 day−1; 4–28 weeks)
(SHRC), (3) SHR administered L-NAME (25mg kg−1 day−1)
(untreated)(SHR/L-NAME), and (4) SHR administered L-
NAME (25mg kg−1 day−1) treated with Clonidine
(0.5mg kg−1 day−1; 4–28 weeks) (SHRC/L-NAME) of which
each group consists of 6 animals (𝑛 = 6). Chronic admin-
istration of L-NAME started in rats aged 16 weeks until 28
weeks in group 3 and group 4. The normotensive Wistar-
Kyoto (WKY) rats were divided and treated with clonidine
in a similar manner with SHR groups.
Systolic blood pressure (SBP) was taken during the exper-
imental period for every two weeks using the tail plethys-
mography blood pressure analyzer (IITC Life Science, USA).
Rats were weighed and sacrificed at the end of 28th weeks.
The heart was collected and homogenized (Glas-Col, USA)
in 0.05M sodium phosphate buffer (pH 7.4). Supernatant of
heart homogenate was stored at −70∘C until use for biochem-
ical analysis.
Lipid peroxidation was determined as thiobarbituric acid
reactive substances (TBARS) according to the method of
Chatterjee et al. [14]. MDA, an end product of fatty acid
peroxidation, react with TBA to form coloured complex
which has maximum absorbance at 532 nm. 1,1,3,3-Tetrae-
thoxypropane (TEP); a form ofMDAwas used as standard in
this assay. 0.1% of heart homogenate orMDA standard (2 𝜇M,
4 𝜇M, 6𝜇M, and 8 𝜇M) were pipette into each test tubes. The
test tubes were vortexed and then kept in boilingwater bath at
95∘C for 60minutes. After cooling, the tubeswere centrifuged
at 3000×g for 10 minutes. One mL of each supernatant was
transferred to semimicrocuvette and absorbance was read at
532 nm on a spectrophotometer.
Protein carbonyl (PCO) levels were determined using
Protein Carbonyl Assay Kit (Cayman, USA) according to the
method of Rohrbach et al. [15]. DNHP react with protein
carbonyl, forming a Schiff base to produce corresponding
hydrazone. The amount of protein-hydrazone produced was
quantified spectrophotometrically at an absorbance between
360 and 385 nm.
Total antioxidant status (TAS) was assessed according
to the method of Koracevic et al. [16]. It was based on the
principle that a standardized solution of Fe-EDTA complex
reacted with hydrogen peroxide by a Fenton-type reaction,
leading to the formation of hydroxyl radicals. These reactive
oxygen species degraded benzoate, resulting in the release
of TBARS. Antioxidants from the added sample of heart
homogenate caused suppression of the production of TBARS
that was proportional to their concentration. This reaction
was measured spectrophotometrically at 532 nm and the
inhibition of colour development was defined as the TAS.
Nitric Oxide (NO) was determined using Nitrate/Nitrite
Colorimetric Assay Kit according to the method Yui et al.
[17]. Nitrate reductase utilizes NADPH in the enzymatic
reduction of nitrate to nitrite. Nitrite produced reacts with
Griess Reagent 1 followed byGriess Reagent 2 to produce Azo
product. The concentration of the Azo product in the sample
was obtained by measuring the absorbance at 540 nm.
3. Statistical Analysis
Data were analyzed using One-Way ANOVA with post hoc
Tukey test. Data were analyzed using Statistical Package for
the Social Science (SPSS) software version 20. Significant level
was set at (𝑃 < 0.05). Data are expressed as mean and stand-
ard error mean (mean ± SEM) for six animals in each group.
4. Results
4.1. SBP, Oxidative Stress Parameters, and NO of Clonidine
Treated and Untreated SHR and SHR+L-NAME. The SBP of
Clonidine treated and untreated SHR and SHR+L-NAME
were presented in Figure 1. SBPof SHR treatedwithClonidine
(SHRC) were significantly lower from age of 8 weeks until 28
weekswhen compared to untreated SHR (𝑃 < 0.001, a∗∗∗). L-
NAMEwas administered to rats at age of 16 weeks.Therefore,
SHR+L-NAME treated with Clonidine (SHRC+L-NAME)
showed significant increase compared to untreated SHR+L-
NAME (c∗∗∗, 𝑃 < 0.001), before L-NAME was administered
as these still represent the SHRC compared to SHR. After
administration of L-NAME, SHR+L-NAME showed signif-
icant increase in SBP in weeks 26 (𝑃 < 0.01, b∗∗) and in
weeks 28 (𝑃 < 0.001, b∗∗∗) compared to SHR. There was
also significant decrease of SBP in Clonidine treated SHR
administered L-NAME (SHRC+L-NAME) when compared
to untreated SHR+L-NAME from weeks 20 until weeks 28
(week 20: 𝑃 < 0.05, d∗, week 22 and 24: 𝑃 < 0.01, d∗∗, and
week 26 & 28: 𝑃 < 0.001, d∗∗∗).
4.2. TAS. Figure 2 represents the level of TAS in Clonidine
treated and untreated SHR and SHR+L-NAME. The level of
TAS was significantly increased with Clonidine treatment in
SHR (𝑃 < 0.001, a∗∗∗). However, no significant difference in
TAS level in L-NAME administered SHR when compared to
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Figure 1: SBP of Clonidine treated and untreated SHR administered with L-NAME. a∗∗∗ 𝑃 < 0.001 SHR compared to SHRC, b∗∗ 𝑃 < 0.01
SHR+L-NAME compared to SHR, c∗∗∗ 𝑃 < 0.001 SHRC+L-NAME compared to SHR+L-NAME and d∗ 𝑃 < 0.05, d∗∗ 𝑃 < 0.01, and
d∗∗∗ 𝑃 < 0.001 SHRC+L-NAME compared to SHRC.
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Figure 2: TAS levels in Clonidine treated and untreated SHR
administered with L-NAME. a∗∗∗ 𝑃 < 0.001 SHR compared to
SHRC, c∗∗∗ 𝑃 < 0.001 SHRC+L-NAME compared to SHR+L-
NAME.
SHR. Significant increase was evident in TAS level in Cloni-
dine treated SHR administered with L-NAME (SHRC+L-
NAME) when compared to untreated SHR administered L-
NAME (SHR+L-NAME) (𝑃 < 0.001, c∗∗∗). No significant
difference was observed in SHRC+L-NAMEwhen compared
to Clonidine treated SHR without L-NAME (SHRC).
4.3. TBARS. The TBARS levels of Clonidine treated and
untreated SHR and SHR+L-NAME were provided in Fig-
ure 3. TBARS level in Clonidine treated SHRwas significantly
lower compared to untreated SHR (𝑃<0.001, a∗∗∗).The levels
of TBARS in SHR administered with L-NAME (SHR+L-
NAME) were significantly higher when compared to SHR
(𝑃 < 0.001, b∗∗∗). Significant decrease was evident in
TBARS level in Clonidine treated SHR administered with L-
NAME (SHRC+L-NAME)when compared to untreated SHR
administered L-NAME (SHR+L-NAME) (𝑃 < 0.001, c∗∗∗).
No significant difference was observed in SHRC+L-NAME
when compared to Clonidine treated SHR without L-NAME
(SHRC).
4.4. PCO. Figure 4 represents the PCO level of Clonidine
treated and untreated SHR and SHR+L-NAME. PCO level
in Clonidine treated SHR was significantly lower compared
to untreated SHR (𝑃 < 0.05, a∗). Significant increase
was observed in PCO levels of SHR administered L-NAME
(SHR+L-NAME) when compared to SHR (𝑃 < 0.001, b∗∗∗).
Significant decrease was evident in PCO level in Clonidine
treated SHR administered with L-NAME (SHRC+L-NAME)
when compared to untreated SHR administered L-NAME
(SHR+L-NAME) (𝑃 < 0.05, c∗). Significant increase also was
observed in SHRC+L-NAME when compared to Clonidine
treated SHR without L-NAME (SHRC) (𝑃 < 0.001, d∗∗∗).
4.5. NO. The NO levels of Clonidine treated and untreated
SHR and SHR+L-NAME were given in Figure 5. NO level
in Clonidine treated SHR and SHR+L-NAME was increased
but not statistically significant compared to untreated SHR.
Significant decrease was observed in NO levels of SHR
administered L-NAME (SHR+L-NAME) when compared to
SHR (𝑃 < 0.001, b∗∗∗). No significant difference was evident
in NO level in Clonidine treated SHR administered with
L-NAME (SHRC+L-NAME) when compared to untreated
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Figure 3: TBARS levels in Clonidine treated and untreated SHR
administered with L-NAME. a∗∗∗ 𝑃 < 0.001 SHR compared to
SHRC, b∗∗∗ 𝑃 < 0.001 SHR+L-NAME compared to SHR, and
c∗∗∗ 𝑃 < 0.001 SHRC+L-NAME compared to SHR+L-NAME.
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Figure 4: PCO levels in Clonidine treated and untreated SHR
administered with L-NAME. a∗ 𝑃 < 0.05 SHR compared to SHRC,
b∗∗∗ 𝑃 < 0.001 SHR+L-NAME compared to SHR, c∗ 𝑃 < 0.05
SHRC+L-NAME compared to SHR+L-NAME, and d∗∗∗ 𝑃 < 0.001
SHRC+L-NAME compared to SHRC.
SHR administered L-NAME (SHR+L-NAME). Significant
decrease also was observed in SHRC+L-NAME when com-
pared to Clonidine treated SHR without L-NAME (SHRC)
(𝑃 < 0.001, d∗∗∗).
4.6. SBP, Oxidative Stress Parameters, and NO of Clonidine
Treated and Untreated WKY and WKY+L-NAME. WKY
rats showed normal SBP. As expected, L-NAME adminis-
tration in WKY significantly increases the SBP at 18 weeks
(𝑃 < 0.05) and 20 weeks onward (𝑃 < 0.001) when
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Figure 5: NO levels in Clonidine treated and untreated SHR admin-
istered with L-NAME. b∗∗∗ 𝑃 < 0.001 SHR+L-NAME compared to
SHR and d∗∗∗ 𝑃 < 0.001 SHRC+L-NAME compared to SHRC.
compared toWKY.Clonidine treatment significantly reduced
the SBP in WKY+L-NAME when compared to WKY+L-
NAME untreated (data not shown).
Table 1 showed the oxidative stress parameters and NO
of normotensive WKY rats. Significant increase (b∗∗∗, 𝑃 <
0.001) was evident in TBARS and PCO levels of WKY+L-
NAME when compared to WKY. However, no significant
difference was evident in TAS levels of WKY+L-NAME
when compared to WKY. Clonidine treatment significantly
elevated the TAS level in WKY when compared to untreated
WKY (a∗∗∗, 𝑃 < 0.001), but no significant difference was
seen in PCO levels. TBARS level showed significant increase
in Clonidine treated WKY (a∗, 𝑃 < 0.05) and WKY+L-
NAME (c∗, 𝑃 < 0.05) when compared to their matched
untreated groups. Significant decrease (b∗∗∗ and d∗∗∗, 𝑃 <
0.001) in NO level was evident in L-NAME administered
groups. However, no significant difference was evident in NO
level in Clonidine treated WKY and WKY+L-NAME when
compared to their matched untreated groups.
5. Discussions
The results of this study showed that SBP was significantly
elevated in SHR as demonstrated in previous studies [18, 19].
Administration of L-NAME at 16 weeks initially did not
elevate SBP in SHR. However, at weeks 26 and 28, SBP was
elevated in SHR+L-NAME. Gerova´ et al. [20] showed that
the use of L-NAME as NOS inhibitor alters the regulation
of blood pressure and is accompanied by development of
cardiovascular disorders. It has been shown that chronic
reduction of NO synthesis resulted in hypertension [20, 21]
and reduced endothelial vasorelaxation [22–24] and myocar-
dial hypertrophy [25]. The results of this study demonstrated
that Clonidine can attenuate development of high blood
pressure and end-organ damage in SHR and SHR+L-NAME
with significant endothelial dysfunction produced by inhi-
bition of NO synthesis. Since 1960, Clonidine is believed to
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Table 1: Effect of Clonidine treatment on TBARS, PCO, TAS, and NO level of Clonidine treated and untreatedWKY andWKY administered
L-NAME.
Parameters Groups
WKY WKY+L-NAME WKYC WKYC+L-NAME
TAS 7.64 ± 0.17 6.91 ± 0.05 10.54 ± 0.93 a∗∗∗ 8.53 ± 0.18
TBARS 5.59 ± 0.32 7.49 ± 0.20 b∗∗∗ 7.80 ± 0.49 a∗ 8.98 ± 0.25 c∗
PCO 2.69 ± 0.07 3.12 ± 0.05 b∗∗∗ 2.94 ± 0.18 3.11 ± 0.19 c∗
NO 37.65 ± 0.56 27.92 ± 0.79 b∗∗∗ 39.25 ± 0.65 30.71 ± 0.69 d∗∗∗
Values are expressed as mean ± S.E.M. (𝑛 = 6 per group).
WKY: WKY no treatment, WKY+L-NAME: WKY no treatment+L-NAME, WKYC: WKY+Clonidine, and WKYC+L-NAME: WKY+Clonidine+L-NAME.
a∗ P < 0.05, a∗∗∗ P < 0.001 WKY compared to WKYC, b∗∗∗ P < 0.001 WKY+L-NAME compared to WKY, c∗ P < 0.05 WKYC+L-NAME compared to
WKY+L-NAME, and d∗∗∗ P < 0.001 WKYC+L-NAME compared to WKYC.
lower blood pressure through several modes of action such
as stimulating a-adrenoceptors in the cardiovascular centers
with a reduction of sympathetic nerve activity and nora-
drenaline release [26, 27] producing suppressant effect on
adrenal medullary function, and decreasing adrenal sympa-
thetic nerve activity [28–30], and activation of nonadrenergic
depressor pathways, and activation of baroreflex [31, 32].
Clonidine treatment also delayed the onset and attenu-
ated the severity of hypertension produced by L-NAME inhi-
bition. Rizzoni et al. reported that SHR are normotensive at 4
weeks of age and develop hypertension, cardiac hypertrophy
and vascular dysfunction by 8–12 weeks [33].
The increase in the systolic blood pressure in SHR was
accompanied by changes in the marker of oxidative stress,
such as lower heart total antioxidant status, higher thiobar-
bituric acid reactive substance, and elevation of protein car-
bonyl content. This implies, as previously demonstrated, an
increase in the production of reactive oxygen species, which
in turn produce a higher systemic and heart oxidative stress
in SHR [5]. Alteration in oxidant-antioxidant balance in SHR
demonstrated in this study may contribute to the generation
and/or maintenance of hypertension via promoting vascular
smooth muscle cell proliferation and hypertrophy as well as
collagen deposition, leading to thickening of vascular media
and narrowing of the vascular lumen as reviewed by Gross-
man [34]. In addition, increase oxidative stress may damage
the endothelium, impair endothelium-dependent vascular
relaxation, and increase vascular contractile activity [35].
The present study demonstrates that nitric oxide synthase
inhibition by L-NAME reduced the nitric oxide level in SHR.
By contrast, administration of L-NAMEwas not affecting the
TAS. L-NAME inhibits the production of vasodilator nitric
oxide.
Regarding Clonidine treatment, data from the study
herein revealed that Clonidine treatment elevated total anti-
oxidant status in SHR. To further evaluate the effect of Cloni-
dine against hypertension-associated oxidative stress, the
lipid peroxidation product (TBARS) and protein oxidation
product (PCO) in heart were examined. Clonidine treatment
decreases the level of lipid peroxidation product and protein
oxidation product in heart of SHR and SHR administered L-
NAME in comparison to untreated groups.
The protective effect of clonidinemay havemultiple com-
ponents in its action. Clonidine, an 𝛼2-adrenergic receptor
agonist, is thought to decrease blood pressure by causing
a reduced sympathetic nerve firing rate with the locus
of its action within the CNS [36]. The same report also
demonstrated that Clonidine treatment results in hypoten-
sive in SHR through action of sympathetic vasoconstrictor
fibers. 𝛼2-Adrenoceptor agonists, such as clonidine, attenuate
hypoxia-induced damage to brain and retinal neurones by a
mechanism of action which likely involves stimulation of a-
adrenoceptors. When compared to Clonidine administered
WKY andWKY+L-NAME (Table 1), Clonidine administered
SHR and SHR+L-NAME showed a significant reduction
in oxidative stress parameters which clearly indicate that
Clonidine is reducing oxidative stress in SHR and SHR+L-
NAME.
From this study, therefore, it concluded that some evident
was found to support the idea that, in addition to the hypoten-
sive effect of Clonidine, this antihypertensive drug enhance
the level of antioxidant status and ameliorate the oxidative
stress which might reduce the hypertension induced heart
damage in SHR and SHR+L-NAME. A better understanding
of the complexity of oxidative stress and hypertension, role
of nitric oxide, and development of new class of antihyper-
tensive drug which ameliorates oxidative stress will likely be
the avenues for future research to prevent hypertension and
hypertension induced cardiovascular complications.
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